ABL1 is an inclusion eligibility criterion in 7 clinical trials for lymphoblastic lymphoma, of which 5 are open and 2 are closed. Of the trials that contain ABL1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [3].

ABL2 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ABL2 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 4 clinical trials for lymphoblastic lymphoma, of which 3 are open and 1 is closed. Of the trials that contain AFF1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR is an inclusion eligibility criterion in 7 clinical trials for lymphoblastic lymphoma, of which 5 are open and 2 are closed. Of the trials that contain BCR status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CBFB status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CEP72 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CEP72 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CRLF2 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CRLF2 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

DEK is an inclusion eligibility criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain DEK status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ELL is an inclusion eligibility criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ELL status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

EPOR is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EPOR status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 2 clinical trials for lymphoblastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 5 clinical trials for lymphoblastic lymphoma, of which 4 are open and 1 is closed. Of the trials that contain FLT3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

IGH is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IKZF1 is an inclusion eligibility criterion in 2 clinical trials for lymphoblastic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 status and lymphoblastic lymphoma as inclusion criteria, 2 are phase 2 (1 open) [3].

IL7R is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IL7R status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK1 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK3 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

KIT is an inclusion eligibility criterion in 2 clinical trials for lymphoblastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 4 clinical trials for lymphoblastic lymphoma, of which 3 are open and 1 is closed. Of the trials that contain KMT2A status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].

LYN is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains LYN status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

MAF is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAFB is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAFB status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 5 clinical trials for lymphoblastic lymphoma, of which 4 are open and 1 is closed. Of the trials that contain MECOM status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].

MLF1 is an inclusion eligibility criterion in 2 clinical trials for lymphoblastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MLF1 status and lymphoblastic lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

MLLT1 is an inclusion eligibility criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MLLT1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MLLT10 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MLLT3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MLLT4 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 2 clinical trials for lymphoblastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and lymphoblastic lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

NRIP3 is an inclusion eligibility criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NRIP3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NUP214 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

PBX1 is an inclusion eligibility criterion in 4 clinical trials for lymphoblastic lymphoma, of which 3 are open and 1 is closed. Of the trials that contain PBX1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

PHF6 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 5 clinical trials for lymphoblastic lymphoma, of which 4 are open and 1 is closed. Of the trials that contain RPN1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1T1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SH2B3 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SH2B3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 4 clinical trials for lymphoblastic lymphoma, of which 3 are open and 1 is closed. Of the trials that contain TCF3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].

TET2 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is an inclusion eligibility criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

TYK2 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TYK2 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

WHSC1 is an inclusion eligibility criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains WHSC1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].